Status:
TERMINATED
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Lead Sponsor:
University of Utah
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Primary Myelofibrosis
Primary Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.
Detailed Description
Pulmonary arterial hypertension: Pulmonary arterial hypertension (PAH) is a disease primarily affecting the small precapillary pulmonary vessels. It is characterized by sustained elevation of the pulm...
Eligibility Criteria
Inclusion
- \> 18 years of age
- Signed Informed Consent
- Subjects diagnosed with Primary Pulmonary Hypertension or Myelofibrosis (primary or secondary)
Exclusion
- Anyone not meeting the above inclusion criteria
- Pregnant women
Key Trial Info
Start Date :
June 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00722254
Start Date
June 1 2006
End Date
February 1 2009
Last Update
March 21 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah
Salt Lake City, Utah, United States, 84132
2
VA Salt Lake City Health Care System
Salt Lake City, Utah, United States, 84148